SCHEMBL160405

SCHEMBL160405

SCc1ncnc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 1/20 0.55
PI4K2B Q8TCG2 1/20 0.55
PI4K2A Q9BTU6 1/20 0.55
PI4KB Q9UBF8 1/20 0.55
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50
PDE4C Q08493 1/20 0.50
PDE4D Q08499 1/20 0.50
HTT P42858 3/20 0.47
ALDH1A1 P00352 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ADORA2A P29274 2/20 0.47
MAPT P10636 4/20 0.46
LMNA P02545 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
EGFR P00533 4/20 0.43
RAB9A P51151 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TSHR P16473 2/20 0.43
GALR3 O60755 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11728330 0.79 PI4KA (0.55) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL3822880 0.79 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL2614518 0.79 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL10751781 0.79 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL1108399 0.76 EGFR (0.53) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL11953072 0.76 ALDH1A1 (0.48) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL3673821 0.75 MAPT (0.54) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL14518819 0.75 PI4KA (0.46) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL8547170 0.73 HTT (0.55) PI4KAPI4K2BPI4K2API4KBPDE4A
SCHEMBL17896286 0.73 KDM4E (0.49) PI4KAPI4K2BPI4K2API4KBPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633207-B2 Quinazoline compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2014-01-21 US disclosed
EP-2611789-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030948-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053174-A1 QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF JAK3, JAK2, TYK2 PI4KA 263/4885PI4K2B 310/4885PI4K2A 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.